Neuroblastoma (NB) is considered as a model of risk-adapted therapy for malignant neoplasms in children. The use of a combination of prognostic factors, such as age, stage of the tumor process, histological variant, and molecular genetic profile of a tumor, makes it possible to identify three risk groups characterized by different intensity of therapy and prognosis. However, the stratification of patients with MYCN-amplified stage 1 NB into a certain risk group and, consequently, the choice of therapeutic tactics for patients in this group vary significantly in the protocols of large cooperative NB study groups. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical